Table of Content

1. Executive Summary
   1.1. Urinary Incontinence Therapeutics Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2023 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
       2.3.3. Global Healthcare Spending Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Drug Type Adoption Analysis
   3.2. Regulatory Landscape
   3.3. Value Chain Analysis
       3.3.1. List of End-user/Marketplaces
           3.3.1.1. Retail
           3.3.1.2. Audiology
           3.3.1.3. E-Commerce
       3.3.2. List of End User (Industry)
   3.4. Key Deals and Mergers
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
4. Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. Urinary Incontinence Therapeutics Market Outlook: Type
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Type, 2018-2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
           4.3.3.1. Urge Incontinence
           4.3.3.2. Overflow Incontinence
           4.3.3.3. Stress Incontinence
           4.3.3.4. Functional Incontinence
           4.3.3.5. Other
   4.4. Market Attractiveness Analysis: Type
   4.5. Urinary Incontinence Therapeutics Market Outlook: Drug Class
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2018-2022
       4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
           4.5.3.1. Anticholinergics
           4.5.3.2. Beta-3 Adrenoceptor Agonists
           4.5.3.3. Alpha Blockers
           4.5.3.4. Estrogen
           4.5.3.5. Desmopressin
           4.5.3.6. Tricyclic Antidepressants
           4.5.3.7. Other
   4.6. Market Attractiveness Analysis: Drug Class
   4.7. Urinary Incontinence Therapeutics Market Outlook: End-user
       4.7.1. Introduction / Key Findings
       4.7.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2018-2022
       4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
           4.7.3.1. Hospitals
           4.7.3.2. Retail Pharmacy
           4.7.3.3. Online Pharmacy
   4.8. Market Attractiveness Analysis: End-user
5. Urinary Incontinence Therapeutics Market Outlook: Region
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018-2022
   5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023-2031
       5.3.1. North America
       5.3.2. Europe
       5.3.3. East Asia
       5.3.4. South Asia and Oceania
       5.3.5. Latin America
       5.3.6. Middle East & Africa
   5.4. Market Attractiveness Analysis: Region
6. North America Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   6.1. Key Highlights
   6.2. Pricing Analysis
   6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       6.3.1. By Country
       6.3.2. By Type
       6.3.3. By Drug Class
       6.3.4. By End-user
   6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       6.4.1. U.S.
       6.4.2. Canada
   6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       6.5.1. Urge Incontinence
       6.5.2. Overflow Incontinence
       6.5.3. Stress Incontinence
       6.5.4. Functional Incontinence
       6.5.5. Other
   6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       6.6.1. Anticholinergics
       6.6.2. Beta-3 Adrenoceptor Agonists
       6.6.3. Alpha Blockers
       6.6.4. Estrogen
       6.6.5. Desmopressin
       6.6.6. Tricyclic Antidepressants
       6.6.7. Other
   6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       6.7.1. Hospitals
       6.7.2. Retail Pharmacy
       6.7.3. Online Pharmacy
   6.8. Market Attractiveness Analysis
7. Europe Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   7.1. Key Highlights
   7.2. Pricing Analysis
   7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       7.3.1. By Country
       7.3.2. By Type
       7.3.3. By Drug Class
       7.3.4. By End-user
   7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       7.4.1. Germany
       7.4.2. France
       7.4.3. U.K.
       7.4.4. Italy
       7.4.5. Spain
       7.4.6. Russia
       7.4.7. Türkiye
       7.4.8. Rest of Europe
   7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       7.5.1. Urge Incontinence
       7.5.2. Overflow Incontinence
       7.5.3. Stress Incontinence
       7.5.4. Functional Incontinence
       7.5.5. Other
   7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       7.6.1. Anticholinergics
       7.6.2. Beta-3 Adrenoceptor Agonists
       7.6.3. Alpha Blockers
       7.6.4. Estrogen
       7.6.5. Desmopressin
       7.6.6. Tricyclic Antidepressants
       7.6.7. Other
   7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       7.7.1. Hospitals
       7.7.2. Retail Pharmacy
       7.7.3. Online Pharmacy
   7.8. Market Attractiveness Analysis
8. East Asia Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   8.1. Key Highlights
   8.2. Pricing Analysis
   8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       8.3.1. By Country
       8.3.2. By Type
       8.3.3. By Drug Class
       8.3.4. By End-user
   8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       8.4.1. China
       8.4.2. Japan
       8.4.3. South Korea
   8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       8.5.1. Urge Incontinence
       8.5.2. Overflow Incontinence
       8.5.3. Stress Incontinence
       8.5.4. Functional Incontinence
       8.5.5. Other
   8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       8.6.1. Anticholinergics
       8.6.2. Beta-3 Adrenoceptor Agonists
       8.6.3. Alpha Blockers
       8.6.4. Estrogen
       8.6.5. Desmopressin
       8.6.6. Tricyclic Antidepressants
       8.6.7. Other
   8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       8.7.1. Hospitals
       8.7.2. Retail Pharmacy
       8.7.3. Online Pharmacy
   8.8. Market Attractiveness Analysis
9. South Asia & Oceania Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   9.1. Key Highlights
   9.2. Pricing Analysis
   9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       9.3.1. By Country
       9.3.2. By Type
       9.3.3. By Drug Class
       9.3.4. By End-user
   9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       9.4.1. India
       9.4.2. Southeast Asia
       9.4.3. ANZ
       9.4.4. Rest of South Asia & Oceania
   9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       9.5.1. Urge Incontinence
       9.5.2. Overflow Incontinence
       9.5.3. Stress Incontinence
       9.5.4. Functional Incontinence
       9.5.5. Other
   9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       9.6.1. Anticholinergics
       9.6.2. Beta-3 Adrenoceptor Agonists
       9.6.3. Alpha Blockers
       9.6.4. Estrogen
       9.6.5. Desmopressin
       9.6.6. Tricyclic Antidepressants
       9.6.7. Other
   9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       9.7.1. Hospitals
       9.7.2. Retail Pharmacy
       9.7.3. Online Pharmacy
   9.8. Market Attractiveness Analysis
10. Latin America Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   10.1. Key Highlights
   10.2. Pricing Analysis
   10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       10.3.1. By Country
       10.3.2. By Type
       10.3.3. By Drug Class
       10.3.4. By End-user
   10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       10.4.1. Brazil
       10.4.2. Mexico
       10.4.3. Rest of Latin America
   10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       10.5.1. Urge Incontinence
       10.5.2. Overflow Incontinence
       10.5.3. Stress Incontinence
       10.5.4. Functional Incontinence
       10.5.5. Other
   10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       10.6.1. Anticholinergics
       10.6.2. Beta-3 Adrenoceptor Agonists
       10.6.3. Alpha Blockers
       10.6.4. Estrogen
       10.6.5. Desmopressin
       10.6.6. Tricyclic Antidepressants
       10.6.7. Other
   10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       10.7.1. Hospitals
       10.7.2. Retail Pharmacy
       10.7.3. Online Pharmacy
   10.8. Market Attractiveness Analysis
11. Middle East & Africa Urinary Incontinence Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2031)
   11.1. Key Highlights
   11.2. Pricing Analysis
   11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018-2022
       11.3.1. By Country
       11.3.2. By Type
       11.3.3. By Drug Class
       11.3.4. By End-user
   11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023-2031
       11.4.1. GCC Countries
       11.4.2. Egypt
       11.4.3. South Africa
       11.4.4. Northern Africa
       11.4.5. Rest of Middle East & Africa
   11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023-2031
       11.5.1. Urge Incontinence
       11.5.2. Overflow Incontinence
       11.5.3. Stress Incontinence
       11.5.4. Functional Incontinence
       11.5.5. Other
   11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023-2031
       11.6.1. Anticholinergics
       11.6.2. Beta-3 Adrenoceptor Agonists
       11.6.3. Alpha Blockers
       11.6.4. Estrogen
       11.6.5. Desmopressin
       11.6.6. Tricyclic Antidepressants
       11.6.7. Other
   11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023-2031
       11.7.1. Hospitals
       11.7.2. Retail Pharmacy
       11.7.3. Online Pharmacy
   11.8. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Pfizer Inc
           12.3.1.1. Overview
           12.3.1.2. Segments and Type
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. AbbVie Inc.
       12.3.3. Astellas Pharma Inc.
       12.3.4. Johnson & Johnson
       12.3.5. Viatris Inc.
       12.3.6. Teva Pharmaceutical Industries Ltd.
       12.3.7. Sanofi S.A.
       12.3.8. GlaxoSmithKline plc
       12.3.9. Boehringer Ingelheim Pharmaceuticals, Inc.
       12.3.10. Bayer AG
       12.3.11. Ferring Pharmaceuticals
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations